

Lung cancer is the most common cause of cancer-related death globally. Nevertheless, molecular technology advancements have provided insights into lung cancer pathogenesis, paving the way for novel potential therapeutic strategies to treat this devastating disease.

Since the publication of the first edition in 2015, there have been rapid lung cancer field advancements. Furthermore, the unprecedented explosion of knowledge over the past 5 years has rendered the discipline of lung cancer more complex and dynamic. Moreover, new crucial information is emerging regarding the biology of lung cancer, including novel treatment approaches. Notably, new techniques are currently gaining ground, both within surgery and radiotherapy, with targeted therapy and immunotherapy being offered to more and more patients.

Therefore, recent advances in the field of lung cancer make the publication of this volume appropriate. The first 15 papers include epidemiology, molecular biology, lung cancer screening, and the subsequent 46 papers describe lung cancer treatment, including surgery, targeted therapy, radiotherapy, and immunotherapy. This volume, *Lung Cancer* (2nd edition), provides up-to-date information regarding lung cancer, which would benefit all the professionals and students involved in this field.

We hope this book regarding the phenomenal advancements in the lung cancer field during the past 5 years will enable the readership to enhance their knowledge and skills.

Toyoaki Hida, MD, PhD

*Vice President, Aichi Cancer Center Hospital,
Nagoya 464-8681, Japan*